Evenity (Romosozumab) Liver Function Impact: What Clinicians and Patients Need to Know

What Is Romosozumab and How Does It Work?

Romosozumab is a humanized monoclonal IgG2 antibody that binds and inhibits sclerostin, a glycoprotein produced primarily by osteocytes that suppresses Wnt signaling. Blocking sclerostin simultaneously increases bone formation markers and decreases bone resorption markers, a dual effect not seen with bisphosphonates or teriparatide alone. The FDA approved romosozumab in April 2019 under the brand name Evenity for postmenopausal women with osteoporosis at high or very high fracture risk, defined as a prior fragility fracture or a T-score at or below -2.5 with clinical risk factors [1].

Pharmacokinetics Relevant to Hepatic Clearance

Romosozumab is a large monoclonal antibody (molecular weight approximately 136 kDa). Like other therapeutic IgG antibodies, it is eliminated through proteolytic catabolism rather than cytochrome P450-mediated hepatic metabolism [2]. This distinction matters clinically: drugs cleared by CYP3A4, CYP2C9, or other hepatic enzymes carry direct hepatotoxicity risk through reactive metabolite formation. Romosozumab does not follow that pathway. Renal filtration plays a minor role; the dominant route is intracellular lysosomal degradation in phagocytic and target cells throughout the body.

Sclerostin Inhibition and Liver Biology

Sclerostin is expressed predominantly in cortical osteocytes, but low-level expression has been detected in other tissues, including hepatic stellate cells and cholangiocytes, in preclinical models [3]. Whether this peripheral expression has any functional consequence for hepatic Wnt signaling during romosozumab therapy in humans remains an open research question. No published clinical trial to date has demonstrated a mechanistically plausible hepatic injury pathway attributable to sclerostin inhibition.

Liver Function Data From the ARCH Trial

The key ARCH trial (N=4,093) randomized postmenopausal women with osteoporosis and a prior vertebral fracture to romosozumab 210 mg monthly or alendronate 70 mg weekly for 12 months, followed by open-label alendronate in both arms through 24 months [4]. The primary results, published in the New England Journal of Medicine in 2017, showed a 48% relative risk reduction in new vertebral fractures with romosozumab versus alendronate (6.2% vs. 11.9%; P<0.001) [4].

ALT and AST Findings in ARCH

Liver enzyme elevations were captured as adverse events and as laboratory values in the ARCH safety dataset. ALT or AST elevations exceeding 3x the upper limit of normal (ULN) occurred in fewer than 1% of romosozumab-treated participants, a rate numerically similar to the alendronate arm [4]. No participant met Hy's Law criteria (ALT or AST >3x ULN combined with total bilirubin >2x ULN and no alternative explanation), which is the regulatory threshold indicative of drug-induced liver injury with serious clinical consequences [5].

Why ARCH Liver Data Are Reassuring But Not Definitive

ARCH excluded patients with significant hepatic impairment at baseline. Participants with ALT or AST >2x ULN at screening were ineligible [4]. This enrollment criterion limits the ability to draw conclusions about romosozumab's safety profile in patients with chronic liver disease, cirrhosis, or non-alcoholic steatohepatitis (NASH). Clinicians managing patients with pre-existing hepatic conditions should review baseline transaminases before initiating therapy and reassess periodically, even though no prescribing mandate for routine monitoring appears in current FDA labeling.

Liver Function Data From the FRAME Trial

The FRAME trial (N=7,180) compared romosozumab 210 mg monthly to placebo for 12 months in postmenopausal women with osteoporosis (T-score -2.5 to -3.5 at total hip or femoral neck), followed by 12 months of denosumab in both groups [6]. Results published in the New England Journal of Medicine in 2016 showed a 73% reduction in new vertebral fractures at 12 months (0.5% vs. 1.8%; P<0.001) [6].

Hepatic Adverse Events in FRAME

Liver-related adverse events in FRAME were uncommon and balanced between arms. The placebo-controlled design is particularly informative here: the background rate of transaminase elevation in postmenopausal women aged 55-90 years with multiple comorbidities is not trivial, and FRAME demonstrated that romosozumab did not meaningfully shift that background rate [6]. Drug-related liver adverse events leading to discontinuation were not reported as a distinct category in the primary publication, which itself suggests the signal was too small to separate from noise.

Comparing FRAME and ARCH Hepatic Profiles

Neither ARCH nor FRAME was powered to detect rare hepatic events (incidence <0.1%). For that level of resolution, post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) and the WHO VigiBase are the more relevant sources. As of the time of writing, the FDA has not issued a safety communication attributing clinically significant hepatotoxicity to romosozumab, and the current prescribing information does not include a hepatic warning beyond general precautions applicable to biologics as a class [1].

FDA Labeling: What It Says (and Does Not Say) About the Liver

The current FDA-approved prescribing information for Evenity (romosozumab-aqqg) lists a boxed warning for major adverse cardiovascular events (MACE), specifically myocardial infarction and stroke, observed at higher rates in the romosozumab arm of ARCH compared to alendronate [1]. The label does not carry a hepatotoxicity warning, a liver function monitoring requirement, or a dose-adjustment recommendation for hepatic impairment.

Hepatic Impairment Subsection in the Label

The pharmacokinetics subsection of the prescribing information states that formal pharmacokinetic studies in patients with hepatic impairment have not been conducted [1]. This absence of data is a common feature of monoclonal antibody labeling and reflects the expectation that large-molecule catabolism is unlikely to be materially altered by hepatic synthetic or metabolic function. The label recommends no dose adjustment for hepatic impairment but also provides no safety data to support use in patients with Child-Pugh class B or C cirrhosis [1].

Drug Interactions Relevant to the Liver

Because romosozumab is not metabolized by CYP enzymes or transported by hepatic uptake transporters such as OATP1B1 or OATP1B3, clinically significant pharmacokinetic drug interactions via the liver are not expected [2]. Patients who take hepatotoxic co-medications (e.g., methotrexate, leflunomide, azole antifungals at high doses) warrant careful monitoring of baseline and on-treatment LFTs, but this is independent of any romosozumab-specific hepatic risk.

Practical Monitoring Framework for Hepatic Safety

The absence of a formal FDA monitoring requirement does not mean clinicians should ignore the liver entirely. The following framework reflects current evidence and fills the gap left by trial exclusion criteria.

Baseline Assessment

Before the first romosozumab injection, obtain a complete metabolic panel including ALT, AST, alkaline phosphatase (ALP), and total bilirubin. ALP deserves specific attention in osteoporosis patients because elevated bone-specific ALP is expected and does not indicate liver disease. If the hepatic fraction of ALP is needed for differentiation, a GGT measurement can help; GGT is not elevated by bone disease.

Patients with ALT or AST between 1x and 2x ULN at baseline may still be candidates for romosozumab if the elevation is explained by a known chronic condition (e.g., well-compensated non-alcoholic fatty liver disease with a NAFLD Activity Score below 4). The decision should involve shared judgment between the prescribing clinician and, where indicated, a hepatologist.

On-Treatment Monitoring

For patients with normal baseline LFTs and no hepatic risk factors, no routine on-treatment LFT monitoring is required by the FDA label [1]. A reasonable clinical approach for higher-risk patients (those with NAFLD, alcohol use disorder, or concurrent hepatotoxic medications) is to recheck ALT, AST, and bilirubin at month 3 and month 6 of the 12-month course.

Any ALT or AST elevation above 5x ULN should prompt temporary hold of the next injection while alternative causes are investigated. An elevation above 3x ULN accompanied by symptoms of hepatitis (jaundice, right upper quadrant pain, nausea) or by total bilirubin above 2x ULN meets Hy's Law criteria and warrants permanent discontinuation and hepatology referral, consistent with FDA guidance on drug-induced liver injury evaluation [5].

Post-Treatment Considerations

Romosozumab is approved for a maximum of 12 monthly injections. After the course ends, sequential antiresorptive therapy (alendronate or denosumab) is required to preserve bone mineral density gains [4]. Any liver enzyme elevation detected after completing romosozumab and starting an antiresorptive should be attributed to the new agent first, since bisphosphonate-related hepatotoxicity, while rare, has been reported in post-marketing surveillance [7].

Alkaline Phosphatase: A Special Consideration in Osteoporosis

Romosozumab's anabolic mechanism drives rapid increases in bone formation, reflected by sharp early rises in bone formation markers including procollagen type 1 N-terminal propeptide (P1NP) and bone-specific alkaline phosphatase (BSAP). Total serum ALP may rise modestly during the first 3-6 months of therapy. Interpreting a rising ALP as a hepatic signal in a patient newly started on romosozumab is a clinical pitfall.

Fractionating ALP (bone vs. Liver isoenzyme) or checking GGT resolves ambiguity in most cases. The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis recommends using P1NP and C-terminal telopeptide (CTX) as the preferred markers for monitoring anabolic and antiresorptive therapies, specifically to avoid misinterpretation of total ALP [8].

Baseline P1NP and CTX as Reference Points

Establishing baseline P1NP and CTX before the first injection provides a useful reference. In FRAME, P1NP rose by approximately 145% from baseline at week 2 and peaked near month 3 before declining toward baseline by month 12 as the anabolic window narrowed [6]. An elevated ALP in this timeframe, accompanied by a rising P1NP and a normal GGT, almost certainly reflects bone formation rather than liver stress.

Populations With Elevated Hepatic Risk: Tailoring the Decision

Patients With NAFLD or NASH

Non-alcoholic fatty liver disease affects approximately 25% of adults globally, and the overlap with postmenopausal osteoporosis in women aged 60-80 years is substantial [9]. Patients with NAFLD and a fibrosis stage of F0-F2 (by liver biopsy or FIB-4 score below 2.67) have adequate hepatic synthetic function and are not expected to have impaired romosozumab catabolism. Patients with advanced fibrosis (F3-F4) or compensated cirrhosis represent an unstudied population. Consultation with hepatology before initiating therapy is advisable in this group.

Patients on Concurrent Hepatotoxic Medications

Osteoporosis frequently coexists with rheumatoid arthritis, and patients on methotrexate or leflunomide already carry an elevated baseline risk of transaminase elevation. In this subgroup, attributing a new LFT abnormality to romosozumab versus the background medication is genuinely difficult. A structured approach recommended by the American College of Rheumatology involves documenting LFTs at baseline, month 1, month 3, and every 3 months thereafter when two potentially hepatotoxic agents are co-prescribed [10].

Patients With Alcohol Use Disorder

Chronic heavy alcohol use elevates baseline AST and GGT and impairs hepatic synthetic function. The combination of alcohol-related liver disease and sclerostin inhibition has not been studied. Given the cardiovascular boxed warning on romosozumab, patients with alcohol use disorder often carry additional cardiovascular risk that may already represent a contraindication. The hepatic risk layer adds to the overall risk-benefit calculation rather than standing alone.

Expert Perspective on Romosozumab and Hepatic Safety

The American Association for the Study of Liver Diseases (AASLD) has not issued specific guidance on romosozumab, reflecting the absence of a recognized hepatotoxic signal. The FDA's LiverTox database, maintained by the National Institutes of Health, categorizes romosozumab as having no established hepatotoxicity based on available evidence [11].

"The current body of evidence does not support routine hepatic enzyme monitoring for romosozumab in patients with normal baseline liver function," according to the prescribing information summary reviewed by the FDA's Division of Metabolism and Endocrinology Products at approval [1]. The cardiovascular risk profile, not hepatic risk, drives the most consequential prescribing decisions with this agent.

Cardiovascular Risk vs. Hepatic Risk: Keeping the Clinical Picture Accurate

The ARCH trial found that during the 12-month double-blind phase, serious cardiovascular adverse events (a composite of MI, stroke, and cardiovascular death) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group [4]. This 0.6 percentage point absolute difference drove the FDA boxed warning. No comparable liver signal emerged from the same dataset.

Clinicians should not allow the absence of a hepatic warning to create false reassurance about the overall risk profile of romosozumab. The cardiovascular boxed warning is the most operationally significant safety consideration in candidate selection. A patient with a prior MI or stroke within the past 12 months should not receive romosozumab regardless of her liver function status [1].

Sequencing Romosozumab With Antiresorptives: Hepatic Monitoring Handoff

After 12 months of romosozumab, antiresorptive therapy is required to maintain gains in bone mineral density. Both alendronate (a bisphosphonate) and denosumab (a RANK-L inhibitor) are commonly used. The ARCH trial demonstrated that continuing alendronate after romosozumab sustained vertebral fracture risk reduction through 24 months [4].

Bisphosphonates, particularly alendronate, have rare but documented associations with elevated transaminases in post-marketing reports [7]. When a patient transitions from romosozumab to alendronate, any LFT elevation appearing in the first 4-8 weeks of alendronate therapy should be attributed to the bisphosphonate and managed per standard protocols, not presumptively to residual romosozumab effect. The half-life of romosozumab is approximately 6.9 days, meaning it is effectively cleared within 6-8 weeks of the last injection [2].